Ishizuka O, Mattiasson A, Andersson K E
Department of Urology, Lund University Hospital, Sweden.
J Urol. 1995 Oct;154(4):1548-51.
The urodynamic effects of intrathecal neurokinin (NK) receptor blockade on L-dopa-induced bladder hyperactivity were investigated in a rat model.
Continuous cystometry was performed in normal, conscious, female Sprague-Dawley rats.
In rats pretreated with intraperitoneal carbidopa 50 mg./kg., intraperitoneal L-dopa 50 mg./kg. caused bladder hyperactivity that could be attenuated by intrathecal administration of the NK1 receptor selective antagonist SR 140,333 (2 nmol.), whereas the NK2 receptor selective antagonist SR 48,968 (2 nmol.) failed to do so. Combination of SR 140,333 (2 nmol.) and SR 48,968 (2 nmol.), which by itself decreased micturition pressure, practically abolished the L-dopa-induced hyperactivity.
The present results suggest that tachykinins, via stimulation of NK1 (and/or NK2) receptors, are involved in L-dopa-induced bladder hyperactivity, most probably at the spinal level. This implies tachykinin involvement in the supraspinal pathways that control the sacral parasympathetic center innervating the urinary bladder. It also implies that spinal NK receptors are a possible target for drugs aimed for elimination of bladder hyperactivity mediated via these pathways.
在大鼠模型中研究鞘内神经激肽(NK)受体阻断对左旋多巴诱导的膀胱功能亢进的尿动力学影响。
对正常、清醒的雌性Sprague-Dawley大鼠进行连续膀胱测压。
在腹腔注射50mg/kg卡比多巴预处理的大鼠中,腹腔注射50mg/kg左旋多巴可引起膀胱功能亢进,鞘内注射NK1受体选择性拮抗剂SR 140,333(2nmol)可减轻这种亢进,而NK2受体选择性拮抗剂SR 48,968(2nmol)则无效。SR 140,333(2nmol)和SR 48,968(2nmol)联合使用本身可降低排尿压力,实际上消除了左旋多巴诱导的功能亢进。
目前的结果表明,速激肽通过刺激NK1(和/或NK2)受体参与左旋多巴诱导的膀胱功能亢进,很可能是在脊髓水平。这意味着速激肽参与了控制支配膀胱的骶副交感神经中枢的脊髓上通路。这也意味着脊髓NK受体可能是旨在消除通过这些通路介导的膀胱功能亢进的药物的靶点。